• BMB Reports
• /
• v.50 no.10
• /
• pp.496-503
• /
• 2017

The human body loses several billions of cells daily. When cells die in vivo, the corpse of each dead cell is immediately cleared. Specifically, dead cells are efficiently recognized and cleared by multiple types of neighboring phagocytes. Early research on cell death focused more on molecular mechanisms of cell death regulation while the cellular corpses were merely considered cellular debris. However, it has come to light that various biological stimuli following cell death are important for immune regulation. Clearance of normal dead cells occurs silently in immune tolerance. Exogenous or mutated antigens of malignant or infected cells can initiate adaptive immunity, thereby inducing immunogenicity by adjuvant signals. Several pathogens and cancer cells have strategies to limit the adjuvant signals and escape immune surveillance. In this review, we present an overview of the mechanisms of dead cell clearance and its immune regulations.

• KIPS Transactions on Software and Data Engineering
• /
• v.3 no.10
• /
• pp.389-396
• /
• 2014

There are many defects when we're working on a project. Especially, if we don't have experience in similar field, defects have a strong influence on the system entirely. Therefore, management of risk such like defects is important the factor for success of project. Finally, efficient management of risk can guarantee handling problems such like fault tolerancy, unexpected quality and delay of schedule. In this paper, we propose checkpoint for improvement of reliability and are willing to improve the reliability of an entire system using it.

• Korean Journal of Head & Neck Oncology
• /
• v.33 no.1
• /
• pp.7-13
• /
• 2017

Despite improved treatment outcomes of locally advanced disease over the last 2 decades, the survival of patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) remains dismal. There is a clear need for development of novel therapeutic strategies for recurrent and/or metastatic HNSCC. Recent advances in understanding tumor immunology have been directly and rapidly translated into clinical success of T cell-directed immunotherapeutic approach in the treatment of several types of solid cancers. Among them, impact of immune checkpoint inhibition using neutralizing antibodies is the most striking. A variety of immunotherapeutic strategies targeting T cells have been also studied in HNSCC, especially in recurrent and/or metastatic setting even with significant survival benefit. The present article reviews the basic concept of T cell-directed immunotherapy and the current status of such approaches in the treatment of HNSCC.

• Journal of Institute of Control, Robotics and Systems
• /
• v.10 no.8
• /
• pp.748-754
• /
• 2004

In this paper, we propose the Triple Modular Redundancy (TMR) control system equipped with a checkpoint strategy. In this system, faults in a single processor are masked and faults in two or more processors are detected at each checkpoint time. When faults are detected, the rollback recovery is activated to recover from faults. The conventional TMR control system cannot overcome faults in two or more processors. The proposed system can effectively cope with correlated and independent faults in two or more processors. We develop a reliability model for this TMR control system under correlated and independent transient faults, and derive the reliability equation. Then we investigate the number of checkpoints that maximizes the reliability.

• Proceedings of the Korean Information Science Society Conference
• /
• 2003.04a
• /
• pp.196-198
• /
• 2003

검사점(checkpoint) 오버헤드를 최소화하는 검사점 주기(interval)를 결정하는 것은 결함 허용 시스템(fault tolerant system)에서 검사점 알고리즘과 관련된 많은 연구들의 중요한 목표 중의 하나이다. 검사점을 드물게 하게 되면 실패 후에 재수행 하는데 너무 많은 시간이 필요하게 된다. 반면에, 너무 자주하게 되면 검사점 오버헤드가 커지고 프로그램의 총 실행시간에 영향을 주게 된다. 이 논문에서는 적응성 있는(adaptive) 시계열 (time series) 분석을 사용하여 검사점 간격을 동적으로 조절할 수 있는 메모리 프로파일 검사점 간격 알고리즘을 제안한다. 트레이스에 기반한 시뮬레이션 실험 결과에서. 제안한 동적인 검사점 주기 알고리즘이 고정적인 검사점 주기 알고리즘보다 전체 검사점 오버헤드가 더 작고, 최적의 검사점 간격에 훨씬 근접했음을 알 수 있었다.

• Journal of Yeungnam Medical Science
• /
• v.38 no.4
• /
• pp.366-370
• /
• 2021

Immune checkpoint inhibitors (ICIs) have become the main drugs for programmed cell death receptor-1 or ligand-1 expressing non-small cell lung cancer (NSCLC) combined with conventional chemotherapy. ICIs are generally more tolerable than cytotoxic chemotherapies in terms of toxicity, and ICI-related adverse events are mild and manageable. However, these drugs may lead to unexpected severe adverse events such as immune-related hematologic toxicities, which could be life-threatening. Here, a rare case of a pembrolizumab-related adverse event in a patient with NSCLC who showed early-onset hemolytic anemia and recovered by high-dose steroid and a series of plasma exchanges is reported.

• Molecules and Cells
• /
• v.44 no.5
• /
• pp.356-362
• /
• 2021

An increasing number of studies have revealed an interaction between gut microbiota and tumors. The enrichment of specific bacteria strains in the intestines has been found to modulate tumor growth and influence the mechanisms of tumor treatment. Various bacteria are involved in modulating the effects of chemotherapeutic drugs currently used to treat patients with cancer, and they affect not only gastrointestinal tract tumors but also distant organ tumors. In addition, changes in the gut microbiota are known to be involved in the antitumor immune response as well as the modulation of the intestinal immune system. As a result, the gut microbiota plays an important role in modulating the efficacy of immune checkpoint inhibitors. Therefore, gut microbiota could be considered as an adjuvant treatment option with other cancer treatment or as another marker for predicting treatment response. In this review, we examine how gut microbiota affects cancer treatments.

• Biomolecules & Therapeutics
• /
• v.30 no.4
• /
• pp.299-308
• /
• 2022

T cells are attractive targets for the development of immunotherapy to treat cancer due to their biological features, capacity of cytotoxicity, and antigen-specific binding of receptors. Novel strategies that can modulate T cell functions or receptor reactivity provide effective therapies, including checkpoint inhibitor, bispecific antibody, and adoptive transfer of T cells transduced with tumor antigen-specific receptors. T cell-based therapies have presented successful pre-clinical/clinical outcomes despite their common immune-related adverse effects. Ongoing studies will allow us to advance current T cell therapies and develop innovative personalized T cell therapies. This review summarizes immunotherapeutic approaches with a focus on T cells. Anti-cancer T cell therapies are also discussed regarding their biological perspectives, efficacy, toxicity, challenges, and opportunities.

• Genomics & Informatics
• /
• v.20 no.1
• /
• pp.13.1-13.4
• /
• 2022

A major issue in the use of immune checkpoint inhibitors is their lack of efficacy in many patients. Previous studies have reported that the T cell inflamed signature can help predict the response to immunotherapy. Thus, many studies have investigated mechanisms of immunotherapy resistance by defining the tumor microenvironment based on T cell inflamed and non-T cell inflamed subsets. Although methods of calculating T cell inflamed subsets have been developed, valid screening tools for distinguishing T cell inflamed from non-T cell inflamed subsets using gene expression data are still needed, since general researchers who are unfamiliar with the details of the equations can experience difficulties using extant scoring formulas to conduct analyses. Thus, we introduce TcellInflamedDetector, an R package for distinguishing T cell inflamed from non-T cell inflamed samples using cancer gene expression data via bulk RNA sequencing.

• Annals of Clinical Neurophysiology
• /
• v.24 no.1
• /
• pp.26-29
• /
• 2022

Immune checkpoint inhibitors (ICIs) have emerged as one of the most promising therapeutic options for advanced cancers. While ICIs have improved survival in multiple cancers, their increased use is restricted by various immune-related adverse events. In this report we describe a patient with renal cell carcinoma who received a combination of ICIs, nivolumab plus ipilimumab, and who developed lumbosacral polyradiculoneuropathy. Corticosteroid use was an effective treatment for this patient.